Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/120265
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vives, Marta | - |
dc.contributor.author | Ginestà, Mireia M. | - |
dc.contributor.author | Gracova, Kristina | - |
dc.contributor.author | Graupera i Garcia-Milà, Mariona | - |
dc.contributor.author | Casanovas i Casanovas, Oriol | - |
dc.contributor.author | Capellá, G. (Gabriel) | - |
dc.contributor.author | Serrano Piñol, M. Teresa | - |
dc.contributor.author | Laquente, Berta | - |
dc.contributor.author | Viñals Canals, Francesc | - |
dc.date.accessioned | 2018-02-26T14:32:54Z | - |
dc.date.available | 2018-02-26T14:32:54Z | - |
dc.date.issued | 2013-11-15 | - |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.uri | http://hdl.handle.net/2445/120265 | - |
dc.description.abstract | In this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic models and with cyclophosphamide in an orthotopic ovarian cancer model. In both models, the C-S schedule had the most favourable effect, achieving at least 80% tumour growth inhibition without increased toxicity. Moreover, in the pancreatic cancer model, although peritoneal metastases were observed in control and MTD groups, no dissemination was observed in the MET and C-S groups. C-S treatment caused a decrease in angiogenesis, and its effect on tumour growth was similar to that produced by the MTD followed by anti-angiogenic DC101 treatment. C-S treatment combined an increase in thrombospondin-1 expression with a decrease in the number of CD133+ cancer cells and triple-positive CD133+/CD44+/CD24+ cancer stem cells (CSCs). These findings confirm that the C-S schedule is a challenging clinical strategy with demonstrable inhibitory effects on tumour dissemination, angiogenesis and CSCs. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1002/ijc.28259 | - |
dc.relation.ispartof | International Journal of Cancer, 2013, vol. 133, num. 10, p. 2464-2472 | - |
dc.relation.uri | https://doi.org/10.1002/ijc.28259 | - |
dc.rights | (c) Union for International Cancer Control (UICC), 2013 | - |
dc.source | Articles publicats en revistes (Ciències Fisiològiques) | - |
dc.subject.classification | Quimioteràpia del càncer | - |
dc.subject.classification | Medicaments antineoplàstics | - |
dc.subject.classification | Angiogènesi | - |
dc.subject.classification | Cèl·lules mare | - |
dc.subject.classification | Cèl·lules canceroses | - |
dc.subject.other | Cancer chemotherapy | - |
dc.subject.other | Antineoplastic agents | - |
dc.subject.other | Neovascularization | - |
dc.subject.other | Stem cells | - |
dc.subject.other | Cancer cells | - |
dc.title | Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 641777 | - |
dc.date.updated | 2018-02-26T14:32:55Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 23649709 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
641777.pdf | 125.62 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.